Descripción del proyecto
Desarrollo de políticas sostenibles para el tratamiento del paludismo grave con artesunato rectal
El paludismos mata, cada año, a casi medio millón de niños menores de cinco años en África. La Organización Mundial de la Salud recomienda la administración previa de artesunato rectal, seguida de artesunato inyectable y politerapia con artemisinina, ya que este régimen reduce la letalidad en un 96 %. La eficacia clínica y el efecto a nivel poblacional de este régimen no se conocen muy bien debido a que los datos son incompletos. En consecuencia, la administración del artesunato rectal sigue siendo limitada. El proyecto SEMA ReACT, financiado con fondos europeos, es un estudio observacional de implantación en Zambia y la República Democrática del Congo. El estudio consiste en que los trabajadores sanitarios extrahospitalarios identifiquen, diagnostiquen, traten y hagan un seguimiento de los pacientes con paludismo grave como parte de la gestión extrahospitalaria integrada de casos. El equipo del proyecto evaluará el efecto a nivel de población y, además, comparará algoritmos de tratamiento en zonas remotas y recomendará políticas sostenibles.
Objetivo
Annually, almost 500,000 children under 5 years die from malaria in Africa. Timely access to effective antimalarial therapies is life saving as treatment with pre-referral rectal artesunate (RAS), followed by injectable artesunate and 3 days treatment with ACTs leads to an observed 96% reduction in mortality. Though recommended by the WHO for years, RAS deployment is very limited.
The full treatment paradigm is not always feasible when access to primary healthcare facilities is limited due to lack of transport, non-availability of services, and cost. Rollout has recently been paused as outcomes data is incomplete in these contexts making the development of best practice recommendations challenging. Hence the relevance of the proposed study.
The proposed project is an observational, non-inferiority study in Zambia and DRC. Community Health Care Workers will identify/diagnose, treat and follow up patients with (severe) malaria as part of integrated community case management. We will compare the efficacy of a treatment regimen consisting of pre-referral RAS, then post-referral injectable artesunate, followed by three days of ACT versus a regimen consisting of RAS alone followed by three days of ACT in remote areas. We will compare recurrence rate between the two regimens at Day 28, the number of lives saved, the risk of generating drug resistance. We will assess and mitigate operational and institutional facilitators and barriers in all stakeholders (patients, caregivers, health care providers, regulators, malaria experts) and recommend sustainable policies for this remote context. This generated evidence will support policy development and implementation.
The proposed consortium brings together vital experience in the rollout and deployment of rectal artesunate, study design and execution, social science, data collection and management, stakeholder engagement and translation of research results into clinical practice.
Ámbito científico
Palabras clave
Programa(s)
- HORIZON.2.1 - Health Main Programme
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinador
2000 Antwerpen
Bélgica